Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901)

European Urology 2026

View at publisher
Authors: Louise Emmett, Nathan Papa, Oliver Sartor, Michael J. Morris, Shalini Subramaniam, Megan Crumbaker, Narjess Ayati, Jeffrey Chen, Ken Herrmann, Andrei Gafita, Mina Swiha, A. M. Joshua
+20 more Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Bao Ho, Sobia Khan, Thean Hsiang Tan, Madison Bills, Andrew Nguyen, Thida Thein, George Sidhom, Keith Wong, Andrew James Martin, Michael S. Hofman, Shahneen Sandhu, Hayley Thomas, Martin R. Stockler, Ian D. Davis
DOI: 10.1016/j.eururo.2026.03.026
Cited by: 2
References: 24

Fields of Study & Subjects

Prostate Cancer Treatment and Research Radiopharmaceutical Chemistry and Applications Neuroendocrine Tumor Research Advances

Publication details

Journal / source
European Urology
Publisher
Elsevier BV
Publication date
1 April 2026
Language
EN